Drug profile · INN
romidepsin
ISTODAX
romidepsin (ISTODAX) is a histone deacetylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — romidepsin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
romidepsin (ISTODAX) is a histone deacetylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Histone deacetylase inhibitor
Primary target: Histone deacetylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is romidepsin?
romidepsin (ISTODAX) is a histone deacetylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for romidepsin?
ISTODAX is a marketed brand name for romidepsin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of romidepsin?
romidepsin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.